SG10202105964RA - Hpk1 inhibitors and methods of using same - Google Patents
Hpk1 inhibitors and methods of using sameInfo
- Publication number
- SG10202105964RA SG10202105964RA SG10202105964RA SG10202105964RA SG10202105964RA SG 10202105964R A SG10202105964R A SG 10202105964RA SG 10202105964R A SG10202105964R A SG 10202105964RA SG 10202105964R A SG10202105964R A SG 10202105964RA SG 10202105964R A SG10202105964R A SG 10202105964RA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- same
- hpk1 inhibitors
- hpk1
- inhibitors
- Prior art date
Links
- 101100177670 Caenorhabditis elegans hpk-1 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562184348P | 2015-06-25 | 2015-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202105964RA true SG10202105964RA (en) | 2021-07-29 |
Family
ID=57584335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202105964RA SG10202105964RA (en) | 2015-06-25 | 2016-06-23 | Hpk1 inhibitors and methods of using same |
Country Status (27)
Country | Link |
---|---|
US (3) | US10501474B2 (zh) |
EP (1) | EP3322711B1 (zh) |
JP (3) | JP6898868B2 (zh) |
KR (2) | KR102614872B1 (zh) |
CN (2) | CN107922431B (zh) |
AU (1) | AU2016282289B2 (zh) |
BR (2) | BR122023006150B1 (zh) |
CA (1) | CA2989684A1 (zh) |
CY (1) | CY1124489T1 (zh) |
DK (1) | DK3322711T3 (zh) |
EA (1) | EA035421B1 (zh) |
ES (1) | ES2872555T3 (zh) |
HK (1) | HK1255833A1 (zh) |
HR (1) | HRP20210895T1 (zh) |
HU (1) | HUE054159T2 (zh) |
IL (2) | IL283353B (zh) |
LT (1) | LT3322711T (zh) |
MA (1) | MA42456B1 (zh) |
MD (1) | MD3322711T2 (zh) |
MX (2) | MX2018000048A (zh) |
PL (1) | PL3322711T3 (zh) |
PT (1) | PT3322711T (zh) |
RS (1) | RS61919B1 (zh) |
SG (1) | SG10202105964RA (zh) |
SI (1) | SI3322711T1 (zh) |
TW (1) | TWI733679B (zh) |
WO (1) | WO2016205942A1 (zh) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD3322711T2 (ro) * | 2015-06-25 | 2021-07-31 | Univ Health Network | Inhibitori HPK1 și metode de utilizare a acestora |
WO2018049191A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
AR109596A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos pirazolopiridina y sus usos |
US20180228786A1 (en) * | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
WO2018167147A1 (en) | 2017-03-15 | 2018-09-20 | F. Hoffmann-La Roche Ag | Azaindoles as inhibitors of hpk1 |
US20180282282A1 (en) * | 2017-03-30 | 2018-10-04 | Genentech, Inc. | Isoquinolines as inhibitors of hpk1 |
BR112019018093A2 (pt) | 2017-03-30 | 2020-06-16 | F. Hoffmann-La Roche Ag | Compostos, composição, método de inibição de hpk1, métodos para melhorar uma resposta imune e para tratar um distúrbio e usos do composto |
WO2018228920A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
WO2018228925A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
EP3638670B1 (en) | 2017-06-13 | 2021-07-21 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases |
CA3070013A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
CN109721620B (zh) * | 2017-10-27 | 2022-05-13 | 药捷安康(南京)科技股份有限公司 | Hpk1抑制剂及其用途 |
JP7167146B2 (ja) * | 2017-11-06 | 2022-11-08 | ブリストル-マイヤーズ スクイブ カンパニー | Hpk1阻害剤として有用なイソフラノン化合物 |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
MD3755703T2 (ro) * | 2018-02-20 | 2022-10-31 | Incyte Corp | Derivați N-(fenil)-2-(fenil)pirimidin-4-carboxamidă și compuși înrudiți ca inhibitori HPK1 pentru tratarea cancerului |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
JP7386842B2 (ja) * | 2018-07-24 | 2023-11-27 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | ナフチリジン化合物およびその使用 |
CN112601584A (zh) * | 2018-07-24 | 2021-04-02 | 豪夫迈·罗氏有限公司 | 异喹啉化合物及其用途 |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
TW202028207A (zh) | 2018-09-25 | 2020-08-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
TW202024053A (zh) * | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
TW202023558A (zh) * | 2018-10-03 | 2020-07-01 | 美商建南德克公司 | 8-胺基異喹啉化合物及其用途 |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
US11071730B2 (en) * | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
WO2020120257A1 (en) | 2018-12-11 | 2020-06-18 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
AR117472A1 (es) | 2018-12-21 | 2021-08-11 | Celgene Corp | Inhibidores de tienopiridina de ripk2 |
EP3902806A4 (en) * | 2018-12-26 | 2022-09-28 | Janssen Pharmaceutica NV | THIENOPYRIDINONE COMPOUNDS |
AU2020249397A1 (en) | 2019-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Bicyclic HPK1 inhibitors |
US20220177458A1 (en) | 2019-03-26 | 2022-06-09 | Janssen Pharmaceutica Nv | Hpk1 inhibitors |
US20220242870A1 (en) * | 2019-05-17 | 2022-08-04 | Voronoi Inc. | Heterocycle-fused pyrimidine derivative and use thereof |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
MX2022002877A (es) * | 2019-09-13 | 2022-08-08 | Nimbus Saturn Inc | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. |
CN112552293A (zh) * | 2019-09-25 | 2021-03-26 | 珠海宇繁生物科技有限责任公司 | 一种protac小分子化合物及其应用 |
TW202124450A (zh) | 2019-10-18 | 2021-07-01 | 美商四十七股份有限公司 | 用於治療骨髓發育不良症候群及急性骨髓白血病之組合療法 |
JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン, インコーポレイテッド | 抗cd47及び抗cd20による血液癌の治療 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
US20230115523A1 (en) * | 2020-01-09 | 2023-04-13 | Sumitomo Chemical Company, Limited | Heterocyclic compound and harmful arthropod-controlling composition including same |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
CN115867275A (zh) * | 2020-04-13 | 2023-03-28 | 大学健康网络 | 治疗细胞因子释放综合征的方法 |
KR20230006891A (ko) | 2020-05-01 | 2023-01-11 | 길리애드 사이언시즈, 인코포레이티드 | Cd73를 억제하는 2,4-다이옥소피리미딘 화합물 |
WO2021226707A1 (en) * | 2020-05-11 | 2021-11-18 | University Health Network | Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1h-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7h)-one |
WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
JP2023543212A (ja) * | 2020-09-30 | 2023-10-13 | ベイジーン リミテッド | Hpk1阻害剤としての3-[(1h-ピラゾール-4-イル)オキシ]ピラジン-2-アミン化合物及びその使用 |
WO2022098807A1 (en) * | 2020-11-09 | 2022-05-12 | Merck Sharp & Dohme Corp. | 7-azole substituted 2-aminoquinazoline inhibitors of hpk1 |
EP4253386A1 (en) * | 2020-11-24 | 2023-10-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Deuterium-modified thienopyridone compound |
EP4288437A1 (en) | 2021-02-05 | 2023-12-13 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
CN116888127A (zh) * | 2021-03-10 | 2023-10-13 | 轩竹生物科技股份有限公司 | 三并环类hpk1抑制剂及其用途 |
CN116981666A (zh) * | 2021-03-26 | 2023-10-31 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
WO2022226667A1 (en) * | 2021-04-30 | 2022-11-03 | Ontario Institute For Cancer Research (Oicr) | Substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1) |
US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
WO2022253252A1 (en) * | 2021-06-03 | 2022-12-08 | Silexon Biotech Co., Ltd. | Heterocyclic compounds useful as hpk1 inhibitors |
CN115433161A (zh) * | 2021-06-04 | 2022-12-06 | 轶诺(浙江)药业有限公司 | 新型hpk1抑制剂及其制备方法和应用 |
EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117693503A (zh) | 2021-07-20 | 2024-03-12 | 阿斯利康(瑞典)有限公司 | 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺 |
EP4380565A1 (en) * | 2021-08-03 | 2024-06-12 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
WO2023023942A1 (en) * | 2021-08-24 | 2023-03-02 | Biofront Ltd (Cayman) | Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same |
WO2023057882A1 (en) * | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
KR20240093606A (ko) * | 2021-10-15 | 2024-06-24 | 로몬드 테라퓨틱스 인코포레이티드 | 치환된 1H-피라졸로[4,3-c] 퀴놀린, 이의 제조 방법 및 용도 |
CA3234909A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
TW202333754A (zh) * | 2021-12-17 | 2023-09-01 | 大陸商海思科醫藥集團股份有限公司 | 並環雜環衍生物及其在醫藥上的應用 |
US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202333712A (zh) * | 2021-12-22 | 2023-09-01 | 加拿大健康網路大學 | 於急性骨髓性白血病或淋巴瘤之治療 |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023138612A1 (en) * | 2022-01-19 | 2023-07-27 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds useful as hpk1 inhibitors |
WO2023143384A1 (zh) * | 2022-01-27 | 2023-08-03 | 四川海思科制药有限公司 | 一种抑制或降解hpk1激酶的化合物及其在医药中的用途 |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
WO2023151559A1 (zh) * | 2022-02-08 | 2023-08-17 | 和径医药科技(上海)有限公司 | 杂环化合物、包含其的药物组合物及其抗肿瘤应用 |
US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
KR20240077873A (ko) | 2022-11-25 | 2024-06-03 | 충남대학교산학협력단 | 이미다조피리딘 유도체, 이를 유효성분으로 포함하는 약제학적 조성물 및 이를 이용하는 암의 치료 방법 |
WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7314200A (en) * | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
ATE290865T1 (de) | 1999-10-19 | 2005-04-15 | Merck & Co Inc | Tyrosin kinase inhibitoren |
ATE448226T1 (de) * | 2000-09-01 | 2009-11-15 | Novartis Vaccines & Diagnostic | Aza heterocyclische derivate und ihre therapeutische verwendung |
WO2004014375A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
US7119205B2 (en) | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
US8501750B2 (en) | 2007-05-21 | 2013-08-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
PT2262500T (pt) | 2008-04-11 | 2016-08-16 | Merck Patent Gmbh | Derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk) |
WO2009135580A1 (en) | 2008-05-05 | 2009-11-12 | Merck Patent Gmbh | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators |
KR20130116358A (ko) | 2011-02-09 | 2013-10-23 | 에프. 호프만-라 로슈 아게 | Pi3 키나아제 억제제로서 헤테로사이클릭 화합물 |
GB201114212D0 (en) * | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
MD3322711T2 (ro) * | 2015-06-25 | 2021-07-31 | Univ Health Network | Inhibitori HPK1 și metode de utilizare a acestora |
-
2016
- 2016-06-23 MD MDE20180529T patent/MD3322711T2/ro unknown
- 2016-06-23 RS RS20210675A patent/RS61919B1/sr unknown
- 2016-06-23 CN CN201680048058.0A patent/CN107922431B/zh active Active
- 2016-06-23 KR KR1020187001327A patent/KR102614872B1/ko active IP Right Grant
- 2016-06-23 US US15/738,286 patent/US10501474B2/en active Active
- 2016-06-23 AU AU2016282289A patent/AU2016282289B2/en active Active
- 2016-06-23 CN CN202110534553.5A patent/CN113214287B/zh active Active
- 2016-06-23 PL PL16813437T patent/PL3322711T3/pl unknown
- 2016-06-23 KR KR1020237042987A patent/KR20240000617A/ko not_active Application Discontinuation
- 2016-06-23 WO PCT/CA2016/050734 patent/WO2016205942A1/en active Application Filing
- 2016-06-23 DK DK16813437.7T patent/DK3322711T3/da active
- 2016-06-23 EA EA201890059A patent/EA035421B1/ru not_active IP Right Cessation
- 2016-06-23 CA CA2989684A patent/CA2989684A1/en active Pending
- 2016-06-23 LT LTEP16813437.7T patent/LT3322711T/lt unknown
- 2016-06-23 BR BR122023006150-0A patent/BR122023006150B1/pt active IP Right Grant
- 2016-06-23 MX MX2018000048A patent/MX2018000048A/es unknown
- 2016-06-23 PT PT168134377T patent/PT3322711T/pt unknown
- 2016-06-23 JP JP2017566338A patent/JP6898868B2/ja active Active
- 2016-06-23 SI SI201631189T patent/SI3322711T1/sl unknown
- 2016-06-23 MA MA42456A patent/MA42456B1/fr unknown
- 2016-06-23 HU HUE16813437A patent/HUE054159T2/hu unknown
- 2016-06-23 EP EP16813437.7A patent/EP3322711B1/en active Active
- 2016-06-23 SG SG10202105964RA patent/SG10202105964RA/en unknown
- 2016-06-23 IL IL283353A patent/IL283353B/en unknown
- 2016-06-23 BR BR112017027241-5A patent/BR112017027241B1/pt active IP Right Grant
- 2016-06-23 ES ES16813437T patent/ES2872555T3/es active Active
- 2016-06-24 TW TW105120043A patent/TWI733679B/zh active
-
2017
- 2017-12-11 IL IL256250A patent/IL256250B/en active IP Right Grant
-
2018
- 2018-01-08 MX MX2021011435A patent/MX2021011435A/es unknown
- 2018-11-21 HK HK18114909.1A patent/HK1255833A1/zh unknown
-
2019
- 2019-12-06 US US16/705,458 patent/US11059832B2/en active Active
-
2021
- 2021-06-07 HR HRP20210895TT patent/HRP20210895T1/hr unknown
- 2021-06-08 CY CY20211100498T patent/CY1124489T1/el unknown
- 2021-06-11 JP JP2021097834A patent/JP7241810B2/ja active Active
- 2021-07-12 US US17/372,717 patent/US20220002313A1/en active Pending
-
2023
- 2023-03-07 JP JP2023034474A patent/JP2023071911A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283353A (en) | hpk1 inhibitors and methods of using them | |
HK1249513A1 (zh) | Kras的稠合三環抑制劑及其使用方法 | |
HK1259232A1 (zh) | Menin-mll的取代抑制劑及其使用方法 | |
HK1252693A1 (zh) | Egfr抑制劑及其使用方法 | |
HK1246286A1 (zh) | Lrrk2抑制劑及其製備和使用方法 | |
HK1250236A1 (zh) | 用gdf8抑制劑增加力量和功能的方法 | |
EP3268369A4 (en) | Anti-alphavbeta1 integrin inhibitors and methods of use | |
IL267291A (en) | Actonucleotidase inhibitors and methods of using them | |
HK1253049A1 (zh) | 糖基相互作用化合物及其使用方法 | |
GB201514756D0 (en) | Compound and method of use | |
IL259801A (en) | ezh2 inhibitors and methods of using them | |
HK1249497A1 (zh) | Ebna1抑制劑及其使用方法 | |
GB201514760D0 (en) | Compounds and method of use | |
IL282482A (en) | Variants of protoxin-II and methods of use | |
IL282508A (en) | Variants of protoxin-II and methods of use | |
HK1248684A1 (zh) | Usp7抑制劑化合物及使用方法 | |
HK1257171A1 (zh) | 間變性淋巴瘤激酶(alk)和絲氨酸富集蛋白激酶 (sppk)的抑制劑及其使用方法 | |
GB2544343B (en) | Receptacle and its method of manufacture | |
IL266344A (en) | Inhibitors of mtor-deptor interactions and methods of use thereof | |
PT3268376T (pt) | Inibidores de enolase e métodos de tratamento com os mesmos | |
GB201416797D0 (en) | Contianer and method of use thereof |